Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

62 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-09-30

Study Completion Date

2011-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the pathological response rate in operable breast cancer patients treated by neoadjuvant combination: "FEC-Taxotere/Vectibix".

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Breast Cancer Treated by Neoadjuvant Chemotherapy

NCT00425516

Individualized Chemotherapy

COMPLETED PHASE2

Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status

NCT02339532

Breast Cancer

COMPLETED PHASE2

Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency

NCT02789332

Breast Cancer Triple Negative Breast Neoplasms HRpos Breast Neoplasms +1 more

COMPLETED PHASE2

Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer

NCT00630032

Breast Cancer

COMPLETED PHASE3

A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast Cancer

NCT01351597

Recurrent Breast Cancer Metastatic Breast Cancer

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pathological Response Rate

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

vectibix

9mg/kg at D1 of each 21-days cycle

Intervention Type DRUG

fluorouracile

500 mg/m2 at D1 of each 21-days cycle

Intervention Type DRUG

Epirubicine

100 mg/m2 at D1 of each 21-days cycle

Intervention Type DRUG

cyclophosphamide

500 mg/m2 at D1 of each 21 dyas cycle

Intervention Type DRUG

docetaxel

100 mg/m2 at D1 of each 21 days cycle

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ³ 18.- Performance status £ 2 (according to WHO criteria).
* Patient has histologically confirmed, non-metastatic breast cancer, with a clinical tumour diameter of ³ 2 cm
* HR negative and Her-2 negative.
* Clinical stage II and IIIa.
* Patients not previously treated by surgery, radiotherapy, hormone therapy or chemotherapy.· Haematology: o Neutrophil count ≥1.5x109/Lo Platelet count ≥100x109/Lo Leucocyte count \> 3,000/mmo Hb\> 9g/dl· Hepatic Function:o Total bilirubin ≤ 1.5 time the upper normal limit (UNL)o ASAT ≤ 2.5xUNL in absence of liver metastases, or ≤5xUNL in presence of liver metastases ALAT ≤ 2.5xUNL in absence of liver metastases, or ≤5xUNL in presence of liver metastases Alkaline phosphatase ≤ 2.5 time the upper normal limit (UNL)· Renal Function· Creatinine clearance ≥50 mL/min and serum creatinine ≤1.5xUNL· Metabolic Function o Magnesium ≥ lower limit of normal. o Calcium ≥ lower limit of normal.
* Patient with no progressive heart disease, and for whom anthracyclines are not contraindicated (normal FEV).
* Patient has signed the consent forms for participation before inclusion in the trial.
* Member of a Social Security scheme (or a beneficiary of such a scheme) according to the provisions of the law of 9 August 2004.

* Non-measurable tumour.
* Patients have already undergone surgery for their disease or have had primary axillary dissection.
* Patient has already been treated for new breast cancer.
* Patient is a ward.
* Patient has a history of second cancer, with exception of in situ cervical cancer or basocellular skin cancer which is regarded as cured.
* Patient has another disease which is deemed incompatible with the patient being included in the protocol.
* Heart or kidney failure, medullary, respiratory or liver failure.
* Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) £ 1 year before enrollment/randomization
* History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan
* Significant neurological or psychiatric abnormalities.
* Symptomatic or progressive disorder of the central nervous system (CNS) or metastasis at the initial check-up.
* Peripheral neuropathy \> grade 2 (NCI-CTCAE criteria, Version 3.0).
* History of allergy to polysorbate 80.
* Concomitant treatment with a trial drug, participation in another clinical trial within \< 30 days or previous chemotherapy.
* Patient with no fixed address in the next 6 months or living at a distance from the treatment centre so it is difficult to check her progress.
* Prior anti-EGFr antibody therapy (e.g.:cetuximab) or treatment with small molecule EGFr tyrosine kinase inhibitors (e.g.: erlotinib).
* Known previous or ongoing abuse of narcotic drug, other medication or alcohol.
* Any investigational agent within 30 days before initiation of study treatment. - Must not have had a major surgical procedure within 28 days of initiation of treatment.
* Subject unwilling or unable to comply with study requirements.

Exclusion Criteria

* Male patients.
* Her-2 positive patients
* Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment.
* Subject (male or female) is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No